MedTrace Logo

Clinical Significance of Liquid Biopsy in Brain Tumor Patients: a 5-ALA Guided Approach

NCT07420543 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-02-19

No results posted yet for this study

Summary

Glioblastoma (GBM) is the most common and lethal primary brain tumor. Identifying blood biomarkers that reflect the tumor's status is a major unmet need for optimal clinical management. 5-ALA (5-Aminolevulinic Acid) administration leads to the accumulation of fluorescent Protoporphyrin IX (PpIX) in GBM cells, allowing identification during surgery. This project aims to leverage 5-ALA induced fluorescence to maximize the informational power of plasma liquid biopsy as a tool for diagnosis, post-treatment follow-up, and as a prognostic tool in patients with GBM.

Conditions

  • Brain Tumors and/or Solid Tumors Including
  • Glioblastoma
  • Glioblastoma (GBM)
  • Glioblastoma - Category

Sponsors & Collaborators

  • University of Milan

    collaborator OTHER

  • Università degli Studi del Piemonte Orientale Amedeo Avogadro

    collaborator OTHER

  • Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-18
Primary Completion
2026-05-31
Completion
2027-05-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07420543 on ClinicalTrials.gov